Virpax Pharmaceuticals, Inc. (VRPX)
| Market Cap | 3.02M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -13.24M |
| Shares Out | 4.89M |
| EPS (ttm) | -5.91 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 275,389 |
| Open | 0.710 |
| Previous Close | 0.660 |
| Day's Range | 0.582 - 0.710 |
| 52-Week Range | 0.363 - 6.200 |
| Beta | 1.10 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | Nov 14, 2024 |
About VRPX
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal s... [Read more]
Financial Performance
Financial StatementsNews
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering
New York, NY, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a leading investment banking firm, is pleased to announce its role as the sole placement agent in Virpax Pharmaceutical...
Virpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems...
Virpax Pharmaceuticals, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems...
This FactSet Research Analyst Turns Bearish; Here Are Top 4 Downgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments
BERWYN, Pa.--(BUSINESS WIRE)-- #earnings--Virpax Reports 2024 Second Quarter Results and Recent Developments.
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax to Present at Sidoti Virtual Investor Conference August 14-15.
Virpax Regains Compliance with Nasdaq Minimum Bid Price
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Regains Compliance with Nasdaq Minimum Bid Price.
Crude Oil Gains Over 1%; Virpax Pharmaceuticals Shares Spike Higher
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 50 points on Wednesday.
Pain Management-Focused Penny Stock Virpax Pharmaceuticals Surges Over 100% On Wednesday-Here's Why?
Wednesday, Virpax Pharmaceuticals Inc VRPX released results for a Swine Model pilot study for Probudur, Virpax's long-acting liposomal bupivacaine formulation injected at a wound site to provide immed...
What's Going With Penny Stock Virpax Pharmaceuticals On Monday?
Shares of Virpax Pharmaceuticals Inc VRPX are trading higher on Monday on a strong session volume of 22.8 million, as per data from Benzinga Pro.
Virpax Pharmaceuticals Secures $2.5 Million Loan Financing and an Agreement with an Institutional Investor to Negotiate Additional Funding
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Secures $2.5 Million Loan Financing and an Agreement with an Institutional Investor to Negotiate Additional Funding.
Virpax® Pharmaceuticals to Present at 2024 BIO International Convention
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax to Present at 2024 BIO International Convention.
Virpax Announces Pricing of $2.25 Million Public Offering
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Pricing of $2.25M Public Offering.
Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments
BERWYN, Pa.--(BUSINESS WIRE)-- #earnings--Virpax Reports 2024 First Quarter Results and Recent Developments.
Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Results of MTD Study for Probudur. Liposomal Formulation Developed to Provide Both Immediate and Sustained Pain Relief.
Virpax Pharmaceuticals Reports 2023 Year-End Results
BERWYN, Pa.--(BUSINESS WIRE)-- #earnings--Virpax Reports 2023 Year-End Results.
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price.
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Preliminary Results of Probudur™ Pilot Study with the U.S. Army Institute of Surgical Research.
Virpax Pharmaceuticals Announces Results of Special Shareholders Meeting
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Results of Special Shareholders Meeting.
Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing.
Virpax Pharmaceuticals Announces Leadership Transition
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Leadership Transition.
Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent Developments
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Reports 2023 Third Quarter Results and Recent Developments.
Virpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Review
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Review.
Virpax Pharmaceuticals Announces Extension of CRADA with the U.S. Army Institute of Surgical Research
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Extension of CRADA with the U.S. Army Institute of Surgical Research.